A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease
NCT ID: NCT03701555
Last Updated: 2023-04-04
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
139 participants
INTERVENTIONAL
2018-06-19
2021-07-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There are many main aims of the study.
* To check if participants have side effects from different forms of the study medicine. These forms are called PVP001 (liquid in a cup), PVP002 capsule, and PVP003 tablet.
* To check how well PVP003 breaks down gluten.
* To check how much PVP003 participants can take without getting side effects from it.
The study is in 4 parts. At the start of each part of the study, the study doctor will check to determine who can take part at the first study visit. Different groups of participants will be in different parts of the study.
In all parts of the study, some participants will take 1 of the 3 forms of study medicine. Others will take a placebo. In this study, a placebo will look like the form of study medicine but will not have any medicine in it. This means that a placebo can either look like PVP001 liquid in a cup, the PVP002 tablet, or the PVP003 tablet.
In Part 1, different small groups of participants will take lower to higher doses of PVP001 or PVP002 or a placebo. This is to work out the best dose of study medicine to take in other parts of the study. After treatment, participants will regularly visit the clinic to check that they have no problems with their treatment, including any side effects from their treatment.
In Part 2, different small groups will take different doses of PVP001 or PVP002 or a placebo, either with or without a meal that has different amounts of gluten in it. This is to check if PVP001 or PVP002 has broken down gluten in the body. Participants will visit the clinic after treatment to check how much gluten has been broken down in the body.
In Part 3, different small groups will take different doses of PVP003 or a placebo, either with or without a meal that has gluten in it. This is to check if PVP003 has broken down gluten in the body. Participants will visit the clinic after treatment to check if more gluten has broken down in the body.
In Part 4, different small groups will take PVP003 or placebo 3 times a day for 5 days. After treatment, participants will visit the clinic to check that they have no problems with their treatment, including any side effects from their treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gastric Gluten-Degradation Activity of PvP001
NCT03594331
PRV-015 in Gluten-free Diet Non-responsive Celiac Disease
NCT04424927
Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal
NCT00669825
PTG-100 for Patients With Celiac Disease
NCT04524221
Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients
NCT01917630
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Following completion of all screening procedures, eligible participants will be enrolled in the study.
Part 1 of the study in healthy participants will be completed prior to enrollment of any subject in Part 2 of the study. A participant enrolled in Part 1 of the study will participate in one of five dose Cohorts. Enrollment of healthy participants and participants with CeD in each of the five dose Cohorts will occur sequentially, but each of these dose Cohorts will be open to enrollment only after demonstration of the safety and tolerability of the same dose level in healthy participants. A healthy participant enrolled in Part 2 of the study will participate in one of three groups; within Groups 1, 2 and 3 enrollment may occur in parallel. A healthy participant enrolled in Part 3 of the study will participate in one of five groups; within Groups 1 to 5 enrollment will occur sequentially. A healthy participant enrolled in Part 4 of the study will participate in two cohorts; enrollment in Part 4 may occur in parallel with enrollment in Part 3. Each participant will be randomized to one of two possible treatment order. Participants who participate in Part 1 or Part 2 of the study, and who are not ADA positive, may participate in Part 3 or Part 4 of the study. No other participants may participate in more than one Part/Group of the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1, Cohort 1A-1 to 1D-1 Healthy Participants
A single dose of PvP001 placebo, PvP001 100 mg, PvP001 300 mg, or PvP001 900 mg will be administered in ascending order to healthy participants in Cohorts 1A-1, 1B-1, 1C-1, and 1D-1.
PvP001 placebo
placebo
PvP001 100 mg
PvP001 100 mg
PvP001 300 mg
PvP001 300 mg
PvP001 900 mg
PvP001 900 mg
Part 1, Cohort 1E-1 Healthy Participants
A single dose of the maximum feasible dose (MFD) of PvP002 will then be administered to healthy participants in Cohort 1E-1.
Maximum Feasible Dose (MFD) of PvP002
MFD of PvP002
Part 1, Cohort 1A-2 - 1D-2 Celiac Disease (CeD)
A single dose of PvP001 placebo, PvP001 100 mg, PvP001 300 mg, or PvP001 900 mg will be administered in ascending order to participants with CeD in Cohorts 1A-2, 1B-2, 1C-2, and 1D-2.
PvP001 placebo
placebo
PvP001 100 mg
PvP001 100 mg
PvP001 300 mg
PvP001 300 mg
PvP001 900 mg
PvP001 900 mg
Part 1, Cohort 1E-2 CeD
A single dose of the MFD of PvP002 will then be administered to participants with CeD in Cohort 1E-2.
Maximum Feasible Dose (MFD) of PvP002
MFD of PvP002
Part 2, Cohort 2A - Cohort 2C Healthy Participants
Participants will be blinded to the PvP001 dose (placebo or MTD of PvP001) and will also receive MTD of PvP001 following 7 days of PPI treatment.
PvP001 placebo
placebo
Maximum Tolerated Dose (MTD) of PvP001
Maximum Tolerated Dose (MTD) of PvP001
MTD of PvP001 following 7 days of PPI treatment
Maximum Tolerated Dose (MTD) of PvP001 following 7 days of PPI (Proton Pump Inhibitor) treatment
Part 2, Cohort 2D Healthy Participants
Participants will receive PvP001 placebo or MFD of PvP001.
PvP001 placebo
placebo
Maximum Tolerated Dose (MTD) of PvP001
Maximum Tolerated Dose (MTD) of PvP001
Part 2, Cohort 2E Healthy Participants
Participants will receive PvP002 placebo or MFD of PvP002.
Maximum Feasible Dose (MFD) of PvP002
MFD of PvP002
PvP002 placebo
Placebo
Part 2, Cohort 2F- Cohort 2H Healthy Participants
Participants will receive the PvP001 placebo and either 300 mg or 600 mg of PvP001.
PvP001 placebo
placebo
PvP001 300 mg
PvP001 300 mg
PvP001 600 mg
PvP001 600 mg
Part 2, Cohort 2I and Cohort 2J Healthy Participants
Participants will receive the PvP001 placebo and 900 mg of PvP001.
PvP001 placebo
placebo
PvP001 900 mg
PvP001 900 mg
Part 3, Cohorts 3A and 3B Healthy Participants
Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 with pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
PvP003 placebo
Placebo tablet orally.
PvP003
PvP003 tablet orally.
Part 3, Cohorts 3C and 3D Healthy Participants
Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
PvP003 placebo
Placebo tablet orally.
PvP003
PvP003 tablet orally.
Part 3, Cohorts 3E and 3F Healthy Participants
Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution after an approximately 50 milliliter (mL) portion of a standardized 1 gm gluten-containing study meal.
PvP003 placebo
Placebo tablet orally.
PvP003
PvP003 tablet orally.
Part 3, Cohorts 3G and 3H Healthy Participants
Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution before a standardized gluten-free study meal followed approximately 30 minutes later by a standardized 1 gm gluten-containing study meal.
PvP003 placebo
Placebo tablet orally.
PvP003
PvP003 tablet orally.
Part 4, Cohorts 4A and 4B Healthy Participants
Participants will receive multiple dose of PvP003 placebo and 600 mg of PvP003.
PvP003 placebo
Placebo tablet orally.
PvP003
PvP003 tablet orally.
Part 3, Cohorts 3I and 3J Healthy Participants
Participants will receive single dose of PvP003 placebo and 150 mg of PvP003 without pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
PvP003 placebo
Placebo tablet orally.
PvP003 150 mg
PvP003 150 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PvP001 placebo
placebo
PvP001 100 mg
PvP001 100 mg
PvP001 300 mg
PvP001 300 mg
PvP001 900 mg
PvP001 900 mg
Maximum Feasible Dose (MFD) of PvP002
MFD of PvP002
Maximum Tolerated Dose (MTD) of PvP001
Maximum Tolerated Dose (MTD) of PvP001
MTD of PvP001 following 7 days of PPI treatment
Maximum Tolerated Dose (MTD) of PvP001 following 7 days of PPI (Proton Pump Inhibitor) treatment
PvP002 placebo
Placebo
PvP001 600 mg
PvP001 600 mg
PvP003 placebo
Placebo tablet orally.
PvP003
PvP003 tablet orally.
PvP003 150 mg
PvP003 150 mg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male or female age 18- 64 years, inclusive
2. No relevant gastrointestinal symptoms
3. Able to abstain from alcohol for 72 hours prior to the Screening Visit; for 72 hours prior to and after the Cohort Treatment Day (Part 1, Part 2, and Part 3); for 72 hours prior to the Safety Visit (Part 2 and Part 3); and for 72 hours prior to Day 1 of the first Cohort Treatment Period through the Safety Visit (Part 4).
4. A female participant must have a negative pregnancy test at Screening and on Cohort Treatment Day -1 (Part 1, Part 2, and Part 3) or a negative pregnancy test at Screening and on Day -1 of each Cohort Treatment Period (Part 4), and must agree to continue acceptable birth control measures (example, abstinence, a stable hormonal contraceptive, double-barrier method, or vasectomy in partner) from the Screening Visit through the 28 ± 2 days. Follow Up ADA Blood Sampling Visit
5. A male participant must agree to use acceptable birth control measures (e.g., abstinence, latex condom, or vasectomy), or must have a female partner who will continue birth control measures (e.g., abstinence, a stable hormonal contraceptive, or double-barrier method) from the Screening Visit through the 28 ± 2 days Follow Up Anti-Drug Antibody Blood Sampling Visit
6. Able to read and understand English
7. Able to provide written informed consent
8. No use of over-the-counter or prescription medication, except for birth control medications for the duration of the study
9. No history of gastrointestinal diseases or disorders
10. No history of intolerance, sensitivity, or reactions to gluten or any other food or food ingredient
11. Able to maintain a gluten-free diet for 24 hours prior to the Cohort Treatment Day (Part 1, Part 2, and Part 3), or usually ingests meals three times a day (that is, breakfast, lunch, and dinner) and is able to continue doing so during each Cohort Treatment Period (Part 4)
12. Documented history of Celiac Disease in medical records
13. Maintaining a gluten-free diet for ≥6 months
14. No use of over-the-counter or prescription medication, except for birth control medications and those allowed by the study doctor, for the duration of the study.
15. No history of gastrointestinal diseases or disorders, other than Celiac Disease
16. No history of intolerance, hypersensitivity, or reaction to any food or food ingredient
17. Able to continue a gluten-free diet for the duration of the study
Exclusion Criteria
1. Current symptoms or signs of illness
2. Chronic viral infection or immunodeficiency condition
3. Any female who is pregnant, planning to become pregnant during the study, or breast-feeding; any male who is planning to father a child during the study
4. Receipt (or planned receipt) of another investigational medication within 4 weeks prior to the Screening Visit through the duration of the study
5. Alcohol consumption greater than (\>) 5 drinks/week, alcohol consumption within 72 hours prior to any study visit (Part 1, Part 2, and Part 3), alcohol consumption within 72 hours prior to Day 1 of the first Cohort Treatment Period through the Safety Visit (Part 4), or a positive alcohol breathalyzer test at any study visit
6. History of illicit or recreational drug use within the three years prior to the Screening Visit, or a positive urine drug screen at any study visit
7. Use of tobacco or nicotine products, including smoking, smokeless tobacco, e-cigarettes, or nicotine replacement products within 12 months prior to the Screening Visit through the duration of the study
18 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Millennium Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anaheim Clinical Trials
Anaheim, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pultz IS, Hill M, Vitanza JM, Wolf C, Saaby L, Liu T, Winkle P, Leffler DA. Gluten Degradation, Pharmacokinetics, Safety, and Tolerability of TAK-062, an Engineered Enzyme to Treat Celiac Disease. Gastroenterology. 2021 Jul;161(1):81-93.e3. doi: 10.1053/j.gastro.2021.03.019. Epub 2021 Mar 17.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PvP-102-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.